| Segment Reporting – Pharmaceuticals |
|
|||||||
|
|
|
|
|
|
|
| ||
|
|
Merck Serono |
Consumer Health Care |
Pharmaceuticals | |||||
|
EUR million |
Q1 |
Q1 |
Q1 |
Q1 |
Q1 |
Q1 | ||
| ||||||||
|
Sales |
1,344.9 |
1,336.3 |
116.2 |
106.9 |
1,461.2 |
1,443.2 | ||
|
Royalty, license and commission income |
82.3 |
70.5 |
0.3 |
0.7 |
82.6 |
71.2 | ||
|
Total revenues |
1,427.2 |
1,406.8 |
116.6 |
107.6 |
1,543.8 |
1,514.4 | ||
|
Gross margin |
1,221.6 |
1,186.5 |
82.1 |
72.8 |
1,303.7 |
1,259.4 | ||
|
Marketing and selling expenses |
–351.7 |
–322.2 |
–60.6 |
–56.8 |
–412.3 |
–379.0 | ||
|
Royalty, license and commission expenses |
–106.3 |
–116.9 |
–0.4 |
–0.2 |
–106.7 |
–117.0 | ||
|
Administration expenses |
–62.5 |
–62.3 |
–6.0 |
–5.9 |
–68.5 |
–68.3 | ||
|
Other operating expenses and income |
–48.0 |
–65.1 |
–1.5 |
–2.6 |
–49.5 |
–67.7 | ||
|
Research and development |
–305.6 |
–304.4 |
–4.8 |
–4.8 |
–310.5 |
–309.3 | ||
|
Operating result |
148.4 |
178.0 |
7.7 |
1.5 |
156.1 |
179.5 | ||
|
Exceptional items |
1.0 |
– |
– |
– |
1.0 |
– | ||
|
Earnings before interest and tax (EBIT) |
149.4 |
178.0 |
7.7 |
1.5 |
157.1 |
179.5 | ||
|
Net operating assets* |
9,962.2 |
10,359.7 |
306.8 |
310.8 |
10,269.0 |
10,670.5 | ||
|
Segment liabilities* |
–1,229.0 |
–1,268.9 |
–79.9 |
–86.4 |
–1,308.8 |
–1,355.3 | ||
|
Capital spending on property, plant and equipment |
44.8 |
46.0 |
0.6 |
1.4 |
45.5 |
47.4 | ||
|
Investments in intangible assets |
5.1 |
11.5 |
0.1 |
0.3 |
5.2 |
11.8 | ||
|
Depreciation and amortization |
–199.4 |
–181.8 |
–2.6 |
–2.8 |
–202.1 |
–184.5 | ||
|
Impairment losses |
–50.4 |
–17.2 |
– |
– |
–50.4 |
–17.2 | ||
|
Net cash flows from operating activities |
340.8 |
246.1 |
13.8 |
–1.2 |
354.5 |
244.9 | ||
|
Net cash flows from investing activities |
197.4 |
–54.7 |
–0.8 |
–1.3 |
196.7 |
–56.0 | ||
|
Free cash flow |
538.2 |
191.4 |
13.0 |
–2.5 |
551.2 |
188.9 | ||
|
Underlying free cash flow |
273.1 |
191.4 |
13.0 |
–2.5 |
286.1 |
188.9 | ||
|
FCR in % |
19.1 |
13.6 |
11.2 |
–2.3 |
18.5 |
12.5 | ||
|
ROS in % |
10.4 |
12.7 |
6.6 |
1.4 |
10.1 |
11.9 | ||